ANDA 206287, held by Lupin. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 206287 (Mibelas 24 Fe), held by Lupin, was first approved by FDA on May 24, 2016, with 4 approved supplements and 0 published complete response letters.
Mibelas 24 Fe is an estrogen/progestin COC indicated for use by women to prevent pregnancy The efficacy in women with a body mass index of more than 35 kg/m 2 has not been evaluated ( 1, 8.8 ) Mibelas 24 Fe is indicated for use by females of reproductive age to prevent pregnancy. The efficacy of Mibelas 24 Fe in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 24, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mibelas 24 Fe0.02MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Jun 22, 2023 | Supplement 18Labeling · Standard review | Approved | None posted |
| Sep 9, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 9, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 9, 2019 | Supplement 8Manufacturing | Approved | None posted |
| May 24, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters